A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Interferonopathies

Interventions

DRUG: BI 3000202_low dose
DRUG: BI 3000202_high dose

Sponsor

Boehringer Ingelheim